-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Reiterates Overweight on Beta Bionics, Raises Price Target to $32

Benzinga·10/29/2025 13:27:50
Listen to the news
Piper Sandler analyst Matt O'Brien reiterates Beta Bionics (NASDAQ:BBNX) with a Overweight and raises the price target from $26 to $32.